<DOC>
	<DOCNO>NCT01445106</DOCNO>
	<brief_summary>Background : - The PI3K/Akt/mTOR pathway important target cancer promote chemotherapeutic resistance confers poor prognosis many type cancer . - Several inhibitor pathway develop cancer therapeutic . However , process de novo drug development take year , often curtail due diminish activity and/or unforeseen toxicity clinical trial . - One approach expedite development new cancer therapy test drug already approve indication . - Our group show nelfinavir , orally available FDA-approved HIV-1 protease inhibitor use treat HIV/AIDS , inhibit endogenous Akt growth factor receptor induce Akt activity cancer cell . - Importantly , nelfinavir demonstrate dose-dependent cytotoxicity every cell line NCI 60 cell line panel plasma concentration attainable human plasma , profoundly effective cancer cell line select become resistant standard therapy , inhibits tumor growth in-vivo . Objectives : - Because MTD nelfinavir observe prior phase I study HIV patient , objectives Phase I design : - To establish MTD dose limit toxicity drug patient solid Tumors . - To correlate nelfinavir pharmacokinetics baseline activity CYP3A4 assess measure midazolam clearance . - To preliminarily explore biological clinical effect series correlative study involve analysis blood tissue across patient throughout study . Eligibility : -Adults solid tumor refractory , relapse receiving , standard front-line chemotherapy eligible . Design : - Patients receive nelfinavir begin FDA-approved dose HIV patient ( 1250 mg po bid ) . - Dose escalation occur 6 dose level i.e . cohort , MTD reach . - Up 45 patient expect enrolled . - Staging CT scan perform every two cycle .</brief_summary>
	<brief_title>A Phase I Trial Nelfinavir ( Viracept ) Adults With Solid Tumors</brief_title>
	<detailed_description>Background : -The PI3K/Akt/mTOR pathway important target cancer promote chemotherapeutic resistance confers poor prognosis many type cancer . - Several inhibitor pathway develop cancer therapeutic . However , process de novo drug development take year , often curtail due diminish activity and/or unforeseen toxicity clinical trial . - One approach expedite development new cancer therapy test drug already approve indication . - Our group show nelfinavir , orally available FDA-approved HIV-1 protease inhibitor use treat HIV/AIDS , inhibit endogenous Akt growth factor receptor induce Akt activity cancer cell . -Importantly , nelfinavir demonstrate dose-dependent cytotoxicity every cell line NCI 60 cell line panel plasma concentration attainable human plasma , profoundly effective cancer cell line select become resistant standard therapy , inhibits tumor growth in-vivo . Objectives : -Because MTD nelfinavir observe prior phase I study HIV patient , objectives Phase I design : -To establish MTD dose limit toxicity drug patient solid Tumors . -To correlate nelfinavir pharmacokinetics baseline activity CYP3A4 assess measure midazolam clearance . -To preliminarily explore biological clinical effect series correlative study involve analysis blood tissue across patient throughout study . Eligibility : -Adults solid tumor refractory , relapse receiving , standard front-line chemotherapy eligible . Design : - Patients receive nelfinavir begin FDA-approved dose HIV patient ( 1250 mg po bid ) . - Dose escalation occur 6 dose level i.e . cohort , MTD reach . - Up 45 patient expect enrolled . - Staging CT scan perform every two cycle .</detailed_description>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients must histologically confirm solid malignancy Laboratory Pathology Clinical Center/NIH Laboratory Pathology NNMC . Patients must : either relapse following , progress , standard therapy ; current disease state standard effective therapy ; refuse standard therapy case curative option exists . Patients may number chemotherapeutic regimen . Age great equal 18 year age . ECOG performance score less equal 2 . An expected survival great equal 3 month . Patients must capacity willingness sign write informed consent demonstrate willingness comply oral regimen . Patients must normal organ marrow function define : absolute neutrophil count great equal 1,500/mL . platelet great equal 100,000/mL . total bilirubin le 1.5 X upper limit institutional normal . AST ( SGOT ) less equal 2.5 X upper limit institutional normal . ALT ( SGPT ) less equal 2.5 X upper limit institutional normal . Creatinine le 1.5 X upper limit institutional normal . Patients must agree use nonhormonal method birth control , e.g. , barrier method , duration study due possible drug interaction . Patients ask would consent biopsy treatment order provide biologic correlate analysis , optional , patient eligible whether consent . Patients brain metastasis must undergo evaluation appropriate counseling treatment radiation oncology . EXCLUSION CRITERIA : Pregnant lactate woman . Patients chemotherapy biologic agent last 28 day prior enter study . Any concurrent therapy chemotherapeutic agent biologic agent radiation therapy . Patients myocardial infarction six month prior enrollment . Patients uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Patients follow CYP3A4 inhibitor replace medication equivalent medication period study : antiarrhythmic ( amiodarone , quinidine ) , neuroleptic ( pimozide ) , sedative/hypnotic agent ( midazolam , triazolam ) , ergot derivative ( dihydroergotamine , ergonovine , ergotamine , methylergonovine ) , HMGCoA reductase inhibitor ( lovastatin , simvastatin , atorvastatin ) , rifampin , rifabutin , felodipine , nifedipine , sildenafil St. John 's wort . Patients whose baseline medication regimen include 2 medication class carry potential serious side effect , must change becaused potential interaction nelfinavir , must stable new regimen 7 day enrollment . Patients escalate dos corticosteroid noncancerous medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2, 2014</verification_date>
	<keyword>HIV Protease Inhibitor</keyword>
	<keyword>Drug Repositioning</keyword>
	<keyword>Akt/Mtor Inhibitor</keyword>
	<keyword>Targeted Therapy</keyword>
	<keyword>Off - Label Drugs</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Phase I</keyword>
	<keyword>Malignant Tumor</keyword>
</DOC>